{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T22:09:20Z","timestamp":1780524560329,"version":"3.54.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T00:00:00Z","timestamp":1567555200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T00:00:00Z","timestamp":1567555200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s00535-019-01623-4","type":"journal-article","created":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T06:12:16Z","timestamp":1567577536000},"page":"217-226","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Management of refractory ascites attenuates muscle mass reduction and improves survival in patients with decompensated cirrhosis"],"prefix":"10.1007","volume":"55","author":[{"given":"Maiko","family":"Namba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Hiramatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Aikata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichiro","family":"Kodama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsuke","family":"Uchikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Ohya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Morio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatsue","family":"Fujino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Nakahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eisuke","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masami","family":"Yamauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomokazu","family":"Kawaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masataka","family":"Tsuge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michio","family":"Imamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Chayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,4]]},"reference":[{"key":"1623_CR1","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.cgh.2011.08.028","volume":"10","author":"AJ Montano-Loza","year":"2012","unstructured":"Montano-Loza AJ, Meza-Junco J, Prado CM, et al. Muscle wasting is associated with mortality in patients with cirrhosis. Clin Gastroenterol Hepatol. 2012;10:166\u201373.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1623_CR2","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.nut.2014.07.005","volume":"31","author":"T Hanai","year":"2015","unstructured":"Hanai T, Shiraki M, Nishimura K, et al. Sarcopenia impairs prognosis of patients with liver cirrhosis. Nutrition. 2015;31:193\u20139.","journal-title":"Nutrition"},{"key":"1623_CR3","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1093\/gerona\/glq001","volume":"65","author":"Y Yamada","year":"2010","unstructured":"Yamada Y, Schoeller DA, Nakamura E, et al. Extracellular water may mask actual muscle atrophy during aging. J Gerontol A Biol Sci Med Sci. 2010;65:510\u20136.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"1623_CR4","doi-asserted-by":"publisher","first-page":"8061","DOI":"10.3748\/wjg.v20.i25.8061","volume":"20","author":"AJ Montano-Loza","year":"2014","unstructured":"Montano-Loza AJ. Clinical relevance of sarcopenia in patients with cirrhosis. World J Gastroenterol. 2014;20:8061\u201371.","journal-title":"World J Gastroenterol"},{"issue":"11","key":"1623_CR5","doi-asserted-by":"publisher","first-page":"e0151652","DOI":"10.1371\/journal.pone.0151652","volume":"24","author":"E Rom\u00e1n","year":"2016","unstructured":"Rom\u00e1n E, Garc\u00eda-Galcer\u00e1n C, Torrades T, et al. Effects of an exercise programme on functional capacity, body composition and risk of falls in patients with cirrhosis: a randomized clinical trial. PLoS ONE. 2016;24(11):e0151652.","journal-title":"PLoS ONE"},{"key":"1623_CR6","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1097\/MEG.0000000000000986","volume":"29","author":"A Hiraoka","year":"2017","unstructured":"Hiraoka A, Michitaka K, Kiguchi D, et al. Efficacy of branched-chain amino acid supplementation and walking exercise for preventing sarcopenia in patients with liver cirrhosis. Eur J Gastroenterol Hepatol. 2017;29:1416\u201323.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"1623_CR7","first-page":"2670","volume":"85","author":"PJ Snyder","year":"2000","unstructured":"Snyder PJ, Peachey H, Berlin JA, et al. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab. 2000;85:2670\u20137.","journal-title":"J Clin Endocrinol Metab"},{"key":"1623_CR8","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1002\/hep4.1207","volume":"2","author":"M Ohara","year":"2018","unstructured":"Ohara M, Ogawa K, Suda G, et al. Carnitine suppresses loss of skeletal muscle mass in patients with liver cirrhosis. Hepatol Commun. 2018;2:906\u201318.","journal-title":"Hepatol Commun"},{"key":"1623_CR9","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1002\/hep4.1309","volume":"3","author":"Akira Hiramatsu","year":"2019","unstructured":"Hiramatsu Akira, Aikata Hiroshi, Uchikawa Shinsuke, et al. Levocarnitine use is associated with improvement in sarcopenia in patients with liver cirrhosis. Hepatol Commun. 2019;3:345\u201355.","journal-title":"Hepatol Commun"},{"key":"1623_CR10","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s13539-012-0069-3","volume":"3","author":"S Dasarathy","year":"2012","unstructured":"Dasarathy S. Consilience in sarcopenia of cirrhosis. J Cachexia Sarcopenia Muscle. 2012;3:225\u201337.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"1623_CR11","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.jhep.2016.06.007","volume":"65","author":"M Sinclair","year":"2016","unstructured":"Sinclair M, Grossmann M, Hoermann R, et al. Testosterone therapy increases muscle mass in men with cirrhosis and low testosterone: a randomised controlled trial. J Hepatol. 2016;65:906\u201313.","journal-title":"J Hepatol"},{"key":"1623_CR12","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1016\/j.jhep.2016.07.040","volume":"65","author":"S Dasarathy","year":"2016","unstructured":"Dasarathy S, Merli M. Sarcopenia from mechanism to diagnosis and treatment in liver disease. J Hepatol. 2016;65:1232\u201344.","journal-title":"J Hepatol"},{"key":"1623_CR13","doi-asserted-by":"publisher","first-page":"18162","DOI":"10.1073\/pnas.1317049110","volume":"110","author":"J Qiu","year":"2013","unstructured":"Qiu J, Thapaliya S, Runkana A, et al. Hyperammonemia in cirrhosis induces transcriptional regulation of myostatin by an NF-\u03baB-mediated mechanism. Proc Natl Acad Sci USA. 2013;110:18162\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1623_CR14","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1152\/ajpendo.00183.2012","volume":"303","author":"J Qiu","year":"2012","unstructured":"Qiu J, Tsien C, Thapalaya S, et al. Hyperammonemia-mediated autophagy in skeletal muscle contributes to sarcopenia of cirrhosis. Am J Physiol Endocrinol Metab. 2012;303:983\u201393.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"1623_CR15","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1111\/j.1572-0241.2001.04051.x","volume":"96","author":"JP Allard","year":"2001","unstructured":"Allard JP, Chau J, Sandokji K, et al. Effects of ascites resolution after successful TIPS on nutrition in cirrhotic patients with refractory ascites. Am J Gastroenterol. 2001;96:2442\u20137.","journal-title":"Am J Gastroenterol"},{"key":"1623_CR16","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1111\/ajt.12373","volume":"13","author":"T Kaido","year":"2013","unstructured":"Kaido T, Uemoto S. Direct segmental multi-frequency bioelectrical impedance analysis is useful to evaluate sarcopenia. Am J Transpl. 2013;13:2506\u20137.","journal-title":"Am J Transpl"},{"key":"1623_CR17","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s00535-016-1216-y","volume":"51","author":"H Fukui","year":"2016","unstructured":"Fukui H, Saito H, Ueno Y, et al. Evidence-based clinical practice guidelines for liver cirrhosis 2015. J Gastroenterol. 2016;51:629\u201350.","journal-title":"J Gastroenterol"},{"key":"1623_CR18","first-page":"860","volume":"287","author":"Y Yamamura","year":"1998","unstructured":"Yamamura Y, Nakamura S, Itoh S, et al. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther. 1998;287:860\u20137.","journal-title":"J Pharmacol Exp Ther"},{"key":"1623_CR19","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1152\/jappl.1998.85.1.115","volume":"85","author":"N Mitsiopoulos","year":"1998","unstructured":"Mitsiopoulos N, Baumgartner RN, Heymsfield SB, et al. Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography. J Appl Physiol. 1998;85:115\u201322.","journal-title":"J Appl Physiol"},{"key":"1623_CR20","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1111\/hepr.12774","volume":"46","author":"H Nishikawa","year":"2016","unstructured":"Nishikawa H, Shiraki M, Hiramatsu A, et al. Japan Society of Hepatology guidelines for sarcopenia in liver disease (1st edition): recommendation from the working group for creation of sarcopenia assessment criteria. Hepatol Res. 2016;46:951\u201363.","journal-title":"Hepatol Res"},{"key":"1623_CR21","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1007\/s00535-017-1366-6","volume":"53","author":"Y Hiramine","year":"2018","unstructured":"Hiramine Y, Uojima H, Nakanishi H, et al. Response criteria of tolvaptan for the treatment of hepatic edema. J Gastroenterol. 2018;53:258\u201368.","journal-title":"J Gastroenterol"},{"key":"1623_CR22","doi-asserted-by":"publisher","first-page":"7420750","DOI":"10.1016\/S0016-5085(19)33439-0","volume":"61","author":"MH Witte","year":"1971","unstructured":"Witte MH, Witte CL, Dumont AE. Progress in liver disease: physiological factors involved in the causation of cirrhotic ascites. Gastroenterology. 1971;61:7420750.","journal-title":"Gastroenterology"},{"issue":"6","key":"1623_CR23","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1172\/JCI106078","volume":"48","author":"Fred L. Lieberman","year":"1969","unstructured":"Lieberman FL, Ito S, Reynolds TB. Effective plasma volume in cirrhosis with ascites. Evidence that a decreased value dose not account for renal sodium retention, a spontaneous reduction in glomerular filtration rate (GFR), and a fall in GFR during drug-induced diuretics. J Clin Inverst. 1969;48:975\u201381.","journal-title":"Journal of Clinical Investigation"},{"key":"1623_CR24","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1002\/hep.1840080532","volume":"8","author":"RW Schrier","year":"1988","unstructured":"Schrier RW, Arroyo V, Bernardi M, et al. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology. 1988;8:1151\u20137.","journal-title":"Hepatology"},{"key":"1623_CR25","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/hepr.12098","volume":"44","author":"I Sakaida","year":"2014","unstructured":"Sakaida I, Kawasoe S, Kajimura K, et al. Tolvaptan for improvement of hepatic edema: a phase 3, multicenter, randomized, double-blind, placebo-controlled trial. Hepatol Res. 2014;44:73\u201382.","journal-title":"Hepatol Res"},{"key":"1623_CR26","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1111\/hepr.12852","volume":"47","author":"I Sakaida","year":"2017","unstructured":"Sakaida I, Terai S, Kurosaki M, et al. Effectiveness and safety of tolvaptan in liver cirrhosis patients with edema: interim results of post-marketing surveillance of tolvaptan in liver cirrhosis (START study). Hepatol Res. 2017;47:1137\u201346.","journal-title":"Hepatol Res"},{"key":"1623_CR27","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s00228-011-1006-7","volume":"67","author":"N Gassanov","year":"2011","unstructured":"Gassanov N, Semmo N, Semmo M, et al. Vasopressin (AVP) and treatment with arginine vasopressin receptor antagonists (vaptans) in congestive heart failure, liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion (SIADH). Eur J Clin Pharmacol. 2011;67:333\u201346.","journal-title":"Eur J Clin Pharmacol"},{"key":"1623_CR28","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1016\/S0140-6736(08)60695-9","volume":"371","author":"G Decaux","year":"2008","unstructured":"Decaux G, Soupart A, Vassart G. Non-peptide arginine-vasopressin antagonists; the vaptans. Lancet. 2008;371:1624\u201332.","journal-title":"Lancet"},{"key":"1623_CR29","doi-asserted-by":"publisher","first-page":"50","DOI":"10.5049\/EBP.2011.9.2.50","volume":"9","author":"JH Yi","year":"2011","unstructured":"Yi JH, Shin HJ, Kim HJ. V2 receptor antagonist: tolvaptan. Electrolyte Blood Press. 2011;9:50\u20134.","journal-title":"Electrolyte Blood Press"},{"key":"1623_CR30","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1007\/s00535-015-1052-5","volume":"50","author":"I Sakaida","year":"2015","unstructured":"Sakaida I, Nakajima K, Okita K, et al. Can serum albumin level affect the pharmacological action of tolvaptan in patients with liver cirrhosis? A post hoc analysis of previous clinical trials in Japan. J Gastroenterol. 2015;50:1047\u201353.","journal-title":"J Gastroenterol"},{"key":"1623_CR31","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.2169\/internalmedicine.55.6819","volume":"55","author":"T Iwamoto","year":"2016","unstructured":"Iwamoto T, Sakaida I, et al. Predictors of the effect of tolvaptan on the prognosis of cirrhosis. Intern Med. 2016;55:2911\u20136.","journal-title":"Intern Med"},{"key":"1623_CR32","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1111\/hepr.12822","volume":"47","author":"T Kogiso","year":"2017","unstructured":"Kogiso T, Yamamoto K, Kobayashi M, et al. Response to tolvaptan and its effect on prognosis in cirrhosis. Hepatol Res. 2017;47:835\u201344.","journal-title":"Hepatol Res"},{"key":"1623_CR33","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1111\/jgh.14047","volume":"33","author":"M Atsukawa","year":"2018","unstructured":"Atsukawa M, Tsubota A, Kato K, et al. Analysis of factors predicting the response to tolvaptan in patients with liver cirrhosis and hepatic edema. J Gastroenterol Hepatol. 2018;33:1256\u201363.","journal-title":"J Gastroenterol Hepatol"},{"key":"1623_CR34","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s00535-016-1233-x","volume":"52","author":"I Sakaida","year":"2017","unstructured":"Sakaida I, Terai S, Nakajima K, et al. Predictive factors of the pharmacological action of tolvaptan in patients with liver cirrhosis: a post hoc analysis. J Gastroenterol. 2017;52:229\u201336.","journal-title":"J Gastroenterol"},{"key":"1623_CR35","doi-asserted-by":"publisher","first-page":"5104","DOI":"10.3748\/wjg.v22.i21.5104","volume":"22","author":"A Nakagawa","year":"2016","unstructured":"Nakagawa A, Atsukawa M, Tsubota A, et al. Usefulness of portal vein pressure for predicting the effects of tolvaptan in cirrhotic patients. World J Gastroenterol. 2016;22:5104\u201313.","journal-title":"World J Gastroenterol"},{"key":"1623_CR36","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1253\/circj.CJ-14-0244","volume":"78","author":"T Imamura","year":"2014","unstructured":"Imamura T, Kinugawa K, Fujino T, et al. Increased urine aquaporin-2 relative to plasma arginine vasopressin is a novel marker of response to tolvaptan in patients with decompensated heart failure. Circ J. 2014;78:2240\u20139.","journal-title":"Circ J"},{"key":"1623_CR37","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1007\/s00535-015-1143-3","volume":"51","author":"H Nakanishi","year":"2016","unstructured":"Nakanishi H, Kurosaki M, Hosokawa T, et al. Urinary excretion of the water channel aquaporin 2 correlated with the pharmacological effect of tolvaptan in cirrhotic patients with ascites. J Gastroenterol. 2016;51:620\u20137.","journal-title":"J Gastroenterol"},{"key":"1623_CR38","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1111\/hepr.12616","volume":"46","author":"T Hanai","year":"2016","unstructured":"Hanai T, Shiraki M, Ohnishi S, et al. Rapid skeletal muscle wasting predicts worse survival in patients with liver cirrhosis. Hepatol Res. 2016;46:743\u201351.","journal-title":"Hepatol Res"},{"key":"1623_CR39","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1002\/hep.22853","volume":"49","author":"BA Runyon","year":"2009","unstructured":"Runyon BA, Committee APG. Management of adult patients with ascites due to cirrhosis: an update. Hepatology. 2009;49:2087\u2013107.","journal-title":"Hepatology"},{"key":"1623_CR40","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.jhep.2010.03.001","volume":"53","author":"European Association for the Study of Liver","year":"2010","unstructured":"European Association for the Study of Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010;53:397\u2013417.","journal-title":"J Hepatol"},{"key":"1623_CR41","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.jhep.2011.10.016","volume":"56","author":"G Fede","year":"2012","unstructured":"Fede G, D\u2019Amico G, Arvaniti V, et al. Renal failure and cirrhosis: a systematic review of mortality and prognosis. J Hepatol. 2012;56:810\u20138.","journal-title":"J Hepatol"},{"key":"1623_CR42","doi-asserted-by":"publisher","first-page":"46349","DOI":"10.1038\/srep46369","volume":"7","author":"S Mandai","year":"2017","unstructured":"Mandai S, Furukawa S, Kodama M, et al. Loop diuretics affect skeletal myoblast differentiation and exercise-induced muscle hypertrophy. Sci Rep. 2017;7:46349.","journal-title":"Sci Rep"},{"issue":"2","key":"1623_CR43","doi-asserted-by":"publisher","first-page":"e0192990","DOI":"10.1371\/journal.pone.0192990","volume":"13","author":"Seiko Ishikawa","year":"2018","unstructured":"Ishikawa, Naito S, Iimori S, et al. Loop diuretics are associated with greater risk of sarcopenia in patients with non-dialysis-dependent chronic kidney disease. PLoS One. 2018;13:e0192990.","journal-title":"PLOS ONE"},{"key":"1623_CR44","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.13244","author":"T Hanai","year":"2018","unstructured":"Hanai T, Shiraki M, Miwa T, et al. Effect of loop diuretics on skeletal muscle depletion in patients with liver cirrhosis. Heptol Res. 2018. \nhttps:\/\/doi.org\/10.1111\/hepr.13244\n\n.","journal-title":"Heptol Res"},{"key":"1623_CR45","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1053\/jlts.2002.35927","volume":"8","author":"RB Freeman Jr","year":"2002","unstructured":"Freeman RB Jr, Wiesner RH, Harper A, et al. The new liver allocation system: moving toward evidence-based transplantation policy. Liver Transpl. 2002;8:851\u20138.","journal-title":"Liver Transpl"},{"key":"1623_CR46","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/hep.21563","volume":"45","author":"PS Kamath","year":"2007","unstructured":"Kamath PS, Kim WR. The model for end-stage liver disease. Hepatology. 2007;45:797\u2013805.","journal-title":"Hepatology"},{"key":"1623_CR47","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0899-9007(01)00754-7","volume":"18","author":"M Tajika","year":"2002","unstructured":"Tajika M, Kato M, Mohri H, et al. Prognostic value of energy metabolism in patients with viral liver cirrhosis. Nutrition. 2002;18:229\u201334.","journal-title":"Nutrition"},{"key":"1623_CR48","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1111\/j.1478-3231.2009.02077.x","volume":"29","author":"J Sam","year":"2009","unstructured":"Sam J, Nguyen GC. Protein-calorie malnutrition as a prognostic indicator of mortality among patients hospitalized with cirrhosis and portal hypertension. Liver Int. 2009;29:1396\u2013402.","journal-title":"Liver Int"},{"key":"1623_CR49","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1097\/MCG.0b013e318293a825","volume":"47","author":"J Meza-Junco","year":"2013","unstructured":"Meza-Junco J, Montano-Loza AJ, Baracos VE, et al. Sarcopenia as a prognostic index of nutritional status in concurrent cirrhosis and hepatocellular carcinoma. J Clin Gastroenterol. 2013;47:861\u201370.","journal-title":"J Clin Gastroenterol"},{"key":"1623_CR50","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1056\/NEJMoa0801209","volume":"359","author":"WR Kim","year":"2008","unstructured":"Kim WR, Biggins SW, Kremersetal WK, et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med. 2008;359:1018\u201326.","journal-title":"N Engl J Med"},{"key":"1623_CR51","doi-asserted-by":"publisher","first-page":"482","DOI":"10.7150\/jca.11665","volume":"6","author":"H Nishikawa","year":"2015","unstructured":"Nishikawa H, Kita R, Kimura T, et al. Hyponatremia in hepatocellular carcinoma complicating with cirrhosis. J Cancer. 2015;6:482\u20139.","journal-title":"J Cancer"},{"key":"1623_CR52","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1002\/hep.20871","volume":"42","author":"C Ripoll","year":"2005","unstructured":"Ripoll C, Ba\u00f1ares R, Rinc\u00f3n D, et al. Influence of hepatic venous pressure gradient on the prediction of survival of patients with cirrhosis in the MELD era. Hepatology. 2005;42:793\u2013801.","journal-title":"Hepatology"},{"key":"1623_CR53","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/j.cgh.2006.08.007","volume":"4","author":"R Planas","year":"2006","unstructured":"Planas R, Montoliu S, Balleste B, et al. Natural history of patients hospitalized for management of cirrhotic ascites. Clin Gastroenterol Hepatol. 2006;4:1385\u201394.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1623_CR54","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.bpg.2006.07.012","volume":"21","author":"A Cardenas","year":"2007","unstructured":"Cardenas A, Arroyo V. Management of ascites and hydrothorax. Best Pract Res Clin Gastroenterol. 2007;21:55\u201375.","journal-title":"Best Pract Res Clin Gastroenterol"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-019-01623-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00535-019-01623-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-019-01623-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T23:34:52Z","timestamp":1599089692000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00535-019-01623-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,4]]},"references-count":54,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["1623"],"URL":"https:\/\/doi.org\/10.1007\/s00535-019-01623-4","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,4]]},"assertion":[{"value":"29 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Kazuaki Chayama received honororira from Eizai, AbbVie, Gilead, Dainippon Sumitomo, Bristol-Myers Squibb, Mitsubishi Tanabe and Othuka, and research funding from Dainippon Sumitomo, The Chugoku Electric Power, Toray, EA Pharma, AbbVie, Eizai, Otsuka, MSD, Daiichi Sankyo, Takeda, Roche, Nippon Kayaku, Bristol-Myers Squibb and Mochida Phamaceutical.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}